JiangSu WuZhong Pharmaceutical Development Co., Ltd. Stock

Equities

600200

CNE000000YP4

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-05-19 pm EDT 5-day change 1st Jan Change
11.23 CNY +2.65% Intraday chart for JiangSu WuZhong Pharmaceutical Development Co., Ltd. +6.24% +36.62%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Sales 2024 * 2.82B 389M Sales 2025 * 3.25B 449M Capitalization 7.91B 1.09B
Net income 2024 * 136M 18.79M Net income 2025 * 221M 30.54M EV / Sales 2024 * 2.81 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 2.44 x
P/E ratio 2024 *
58.5 x
P/E ratio 2025 *
36.5 x
Employees 1,050
Yield 2024 *
0.45%
Yield 2025 *
0.71%
Free-Float 78.13%
More Fundamentals * Assessed data
Dynamic Chart
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. cancelled the transaction announced on April 25, 2023 CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Jiangsu WuZhong Pharma to Invest 30 Million Yuan in Local Biotech Firm MT
Wuzhong Pharmaceutical Development's Unit Gets Registration Certificate for Linezolid Sodium Chloride Injection MT
JiangSu WuZhong Pharmaceutical Development Co., Ltd.(XSSC:600200) added to S&P Global BMI Index CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. cancelled the transaction announced on November 11, 2021 CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. announced that it expects to receive CNY 1.2 billion in funding from Zhejiang Fuji Holdings Group Co., Ltd. and other investors CI
Cinkate Medicine Chemical Intermediate Co., Ltd. agreed to acquire 15% stake in Suzhou Changzheng Cinkate Pharmaceutical Co., Ltd. from JiangSu WuZhong Pharmaceutical Development Co., Ltd. for CNY 33 million. CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
More news
1 day+2.65%
1 week+6.24%
Current month+2.46%
1 month+2.65%
3 months+31.65%
6 months+20.24%
Current year+36.62%
More quotes
1 week
10.24
Extreme 10.24
11.47
1 month
10.11
Extreme 10.11
11.99
Current year
6.90
Extreme 6.9
13.88
1 year
6.90
Extreme 6.9
13.88
3 years
5.43
Extreme 5.43
13.88
5 years
4.27
Extreme 4.27
13.88
10 years
4.27
Extreme 4.27
42.47
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 21-03-30
Chairman 59 99-12-31
Director of Finance/CFO 43 19-04-17
Members of the board TitleAgeSince
Director/Board Member 53 14-04-07
Director/Board Member 43 20-11-08
Director/Board Member 56 19-10-24
More insiders
Date Price Change Volume
24-05-20 11.23 +2.65% 41,907,670
24-05-17 10.94 -0.55% 45,797,540
24-05-16 11 +6.18% 53,621,400
24-05-15 10.36 -2.17% 22,531,800
24-05-14 10.59 +0.19% 17,810,410

End-of-day quote Shanghai S.E., May 19, 2024

More quotes
JiangSu WuZhong Pharmaceutical Development Co Ltd, formerly Jiangsu Wuzhong Industrial Co Ltd, is a China-based company mainly engaged in pharmaceutical business. The Company's business includes pharmaceuticals, chemicals and real estate. Pharmaceutical business mainly involves pharmaceutical research, development, manufacture and sales. Chemical business mainly includes research, development, manufacture and sales of organic pigments, dyes and intermediates. Its main production varieties are used to produce reactive dyes and organic pigments. Real estate business includes commercial housing and affordable housing.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
11.23 CNY
Average target price
12.7 CNY
Spread / Average Target
+13.09%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 600200 Stock
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW